

Pharmaceutical company request for oral testimony at the May 15,2020  
Idaho Medicaid Pharmacy & Therapeutics Committee meeting.

Submission # \_01\_

Date request was received: 04/14/2020

Drug: **Vivitrol**

Therapeutic Drug Class: Substance Use Disorder

Pharmaceutical Company: Alkermes

Initially:

This request for oral testimony has been reviewed.

Denied for testimony

**From:** [usmedinfo@alkermes.com](mailto:usmedinfo@alkermes.com) <[usmedinfo@alkermes.com](mailto:usmedinfo@alkermes.com)>

**Sent:** Tuesday, April 14, 2020 11:51 AM

**To:** Eide, Tamara J. <[Tamara.Eide@dhw.idaho.gov](mailto:Tamara.Eide@dhw.idaho.gov)>

**Cc:** [Paul.Thompson@alkermes.com](mailto:Paul.Thompson@alkermes.com)

**Subject:** VIVITROL Testimony for Idaho State P & T Committee Meeting [External Email]

Dear Idaho State P&T Committee,

Thank you for reviewing VIVITROL® on behalf of Alkermes. Please see attached VIVITROL public testimony and references that Dr. Paul Thompson Medical Science Liaison, will be presenting.

Items attached include:

1. VIVITROL Product Testimony
2. VIVITROL Prescribing Information & Medication Guide

Thank you.

Warm Regards,  
US Medical Information  
Alkermes, Inc.

852 Winter Street

Waltham, MA 02451

T + 1 800 848 4876

[USMedInfo@Alkermes.com](mailto:USMedInfo@Alkermes.com)

[www.alkermes.com](http://www.alkermes.com)